Intrinsic Value Partners LLC Sells 7,420 Shares of Moderna, Inc. $MRNA

Intrinsic Value Partners LLC decreased its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 20.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 28,791 shares of the company’s stock after selling 7,420 shares during the quarter. Intrinsic Value Partners LLC’s holdings in Moderna were worth $794,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in MRNA. Deseret Mutual Benefit Administrators raised its holdings in shares of Moderna by 53.3% in the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company’s stock valued at $32,000 after acquiring an additional 392 shares in the last quarter. Parallel Advisors LLC raised its holdings in shares of Moderna by 11.4% in the 1st quarter. Parallel Advisors LLC now owns 4,403 shares of the company’s stock valued at $125,000 after acquiring an additional 451 shares in the last quarter. Blue Sky Capital Consultants Group Inc. raised its holdings in shares of Moderna by 3.8% in the 1st quarter. Blue Sky Capital Consultants Group Inc. now owns 15,119 shares of the company’s stock valued at $429,000 after acquiring an additional 556 shares in the last quarter. Nissay Asset Management Corp Japan ADV raised its holdings in shares of Moderna by 1.4% in the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 40,639 shares of the company’s stock valued at $1,152,000 after acquiring an additional 562 shares in the last quarter. Finally, Empirical Finance LLC raised its holdings in shares of Moderna by 7.3% during the 1st quarter. Empirical Finance LLC now owns 9,215 shares of the company’s stock valued at $261,000 after buying an additional 624 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on MRNA. JPMorgan Chase & Co. set a $26.00 price objective on Moderna in a report on Friday, August 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of Moderna in a report on Saturday, September 27th. Evercore ISI set a $32.00 price objective on Moderna in a report on Friday, August 1st. Citigroup began coverage on Moderna in a report on Friday, August 1st. They set a “neutral” rating and a $40.00 price objective on the stock. Finally, Wells Fargo & Company reissued an “equal weight” rating on shares of Moderna in a report on Sunday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, fourteen have assigned a Hold rating and five have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Moderna has an average rating of “Hold” and a consensus target price of $41.81.

Moderna Price Performance

Shares of Moderna stock opened at $28.49 on Friday. The business’s 50 day simple moving average is $26.30 and its two-hundred day simple moving average is $27.41. The stock has a market capitalization of $11.08 billion, a P/E ratio of -3.78 and a beta of 2.01. Moderna, Inc. has a one year low of $23.15 and a one year high of $62.11.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, topping analysts’ consensus estimates of ($2.99) by $0.86. The business had revenue of $142.00 million for the quarter, compared to analysts’ expectations of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The business’s quarterly revenue was down 41.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. Sell-side analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.